"SEER Program" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cancer registry mandated under the National Cancer Act of 1971 to operate and maintain a population-based cancer reporting system, reporting periodically estimates of cancer incidence and mortality in the United States. The Surveillance, Epidemiology, and End Results (SEER) Program is a continuing project of the National Cancer Institute of the National Institutes of Health. Among its goals, in addition to assembling and reporting cancer statistics, are the monitoring of annual cancer incident trends and the promoting of studies designed to identify factors amenable to cancer control interventions. (From National Cancer Institute, NIH Publication No. 91-3074, October 1990)
Descriptor ID |
D018426
|
MeSH Number(s) |
E05.318.308.970.725 N04.452.859.819.725 N05.715.360.300.715.700.725 N06.850.520.308.970.725
|
Concept/Terms |
SEER Program- SEER Program
- Program, SEER
- SEER Program (National Cancer Institute (U.S.))
- Surveillance, Epidemiology, and End Results Program
|
Below are MeSH descriptors whose meaning is more general than "SEER Program".
Below are MeSH descriptors whose meaning is more specific than "SEER Program".
This graph shows the total number of publications written about "SEER Program" by people in this website by year, and whether "SEER Program" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2005 | 1 | 0 | 1 |
2009 | 0 | 2 | 2 |
2011 | 0 | 2 | 2 |
2013 | 0 | 2 | 2 |
2015 | 0 | 2 | 2 |
2016 | 0 | 4 | 4 |
2017 | 3 | 34 | 37 |
2018 | 3 | 49 | 52 |
2019 | 1 | 10 | 11 |
2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "SEER Program" by people in Profiles.
-
New Nodal Staging for Primary Pancreatic Neuroendocrine Tumors: A Multi-institutional and National Data Analysis. Ann Surg. 2021 07 01; 274(1):e28-e35.
-
COVID-19 and the Surveillance, Epidemiology, and End Results Program: Future considerations for skin cancer research. J Plast Reconstr Aesthet Surg. 2021 Aug; 74(8):1931-1971.
-
Integrated Survival Estimates for Cancer Treatment Delay Among Adults With Cancer During the COVID-19 Pandemic. JAMA Oncol. 2020 12 01; 6(12):1881-1889.
-
Assessment of local tumor ablation and non-interventional management versus partial nephrectomy in T1a renal cell carcinoma. Minerva Urol Nefrol. 2020 Jun; 72(3):350-359.
-
Carcinoma ex pleomorphic adenoma: A review of incidence, demographics, risk factors, and survival. Am J Otolaryngol. 2019 Nov - Dec; 40(6):102279.
-
Development and validation of a risk score to predict the overall survival following surgical resection of hepatocellular carcinoma in non-cirrhotic liver. HPB (Oxford). 2020 03; 22(3):383-390.
-
Salivary Carcinosarcoma: An Extremely Rare and Highly Aggressive Malignancy. Laryngoscope. 2020 05; 130(5):E335-E339.
-
How cancer-specific mortality changes over time after radical cystectomy: Conditional survival of patients with nonmetastatic urothelial carcinoma of the urinary bladder. Urol Oncol. 2019 12; 37(12):893-899.
-
Decreasing secondary primary uterine cancer after breast cancer: A population-based analysis. Gynecol Oncol. 2019 07; 154(1):169-176.
-
Impact of Tumor Size on Cancer-Specific Mortality Rate After Local Tumor Ablation in T1a Renal-Cell Carcinoma. J Endourol. 2019 07; 33(7):606-613.